



Media Contact:

Elizabeth Somers
Director, Business Development
Fujirebio Diagnostics, Inc.
610-240-3812
somerse@fdi.com

Nicole Gray
Senior Account Executive
M Booth & Associates, Inc.
212-481-7000
nicoleg@mbooth.com

FOR IMMEDIATE RELEASE

FUJIREBIO DIAGNOSTICS (FDI) COMPLETES AGREEMENT TO ENABLE RANDOX LABORATORIES TO DEVELOP AND MARKET FDI TUMOR MARKER ASSAYS

In development agreement, Fujirebio Diagnostics and Randox Laboratories to combine FDI tumor marker assays and Randox multiplexing Biochip Array technology for greater diagnostic accuracy

Malvern, Pa. and Crumlin, Northern Ireland, U.K., August 2, 2002 – Fujirebio Diagnostics, Inc. (FDI), a leading oncology diagnostics company, and Randox, Ltd., today announced the completion of an agreement to develop cancer diagnostics assays based on Fujirebio Diagnostics' proprietary antibodies and Randox's unique automated Biochip Array technology.

Under the terms of the agreement, Fujirebio Diagnostics has provided Randox non-exclusive rights to develop and commercialize a tumor marker assay panel incorporating FDI's proprietary antibodies used in the CA125II, CA19-9, CA15-3, CA72-4 and Truquant BR Tumor Marker assays on Randox's patented Biochip Array Technology. Randox will provide Fujirebio Diagnostics with payments based on future product sales. The automated Biochip Array technology allows the simultaneous determination of a panel of diagnostic markers from a single patient sample. The markers can be used in combination or as stand-alone tests. Recent studies demonstrate that multiplexing, or combining assay determinations using the same patient sample, may improve diagnostic performance and provide more flexibility to physicians and laboratories in the future.

"We are pleased to complete this agreement with Randox and consider them to be a valuable addition to our global network of diagnostic partnerships," said Aris Petropoulos, President and Chief Operating Officer, Fujirebio Diagnostics. "The agreement with Randox is in line with our corporate strategy of being a content driven Diagnostics company and allows our standard-of-care markers to be formatted on a cutting-edge platform."



“The Randox multiplexing technology has very real potential to change the way we perform diagnostic assays, particularly in the area of tumor markers,” said Daniel J. O’Shannessy, Ph.D.,

FDI’s Chief Scientific Officer. “Recent studies have demonstrated that the evaluation of multiple markers provides a more complete diagnostic picture which may be of significant benefit for disease management,” he added, “ and may advance our ability to detect disease at an earlier, more treatable stage.”

Randox Laboratories, founded in 1982, is an independently and privately owned company. Randox is the leading British manufacturer of clinical chemistry environmental diagnostic kits and quality control sera. Randox products are used in hospital and veterinary laboratories in over 120 countries throughout the world. For more information, please visit the Randox Web site at www.randox.com.

Fujirebio Diagnostics, Inc., (FDI), is a premier diagnostics company and the industry leader in Tumor Marker assays specializing in the clinical development, manufacturing and commercialization of *in vitro* diagnostic products for the detection, prognosis, and monitoring of human disease states with an emphasis in Oncology. The company, formally Centocor Diagnostics, was acquired by Fujirebio, Inc. of Tokyo, Japan in November 1998. FDI utilizes it’s world wide distribution network to enable access by physicians and patients to it’s diagnostic products. For more information, please visit our web site at www.fdi.com.

FDI-023 08/02

www.fdi.com

#